ArticleJournal of translational medicine2008
Exosomes as a tumor immune escape mechanism: possible therapeutic implications.
Article in Journal of translational medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 106 citations in OpenAlex.
- A multidimensional landscape of extracellular vesicle-mediated tumor drug resistance: mechanisms, biomarkers, engineered drug delivery, and clinical translation.Extracellular vesicles and circulating nucleic acids · 2026Review
- Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment.Frontiers in oncology · 2023Review
- Removal of small extracellular vesicles inhibits the progression of peritoneal dissemination in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Extracellular Vesicles in the Progression and Therapeutic Resistance of Nasopharyngeal Carcinoma.Cancers · 2022Review
- Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis.Translational oncology · 2022Review
- Small extracellular vesicles in cancer.Bioactive materials · 2021Review
- Potential of different cells-derived exosomal microRNA cargos for treating spinal cord injury.Journal of orthopaedic translation · 2021Review
- Exosomal miR‑663b exposed to TGF‑β1 promotes cervical cancer metastasis and epithelial‑mesenchymal transition by targeting MGAT3.Oncology reports · 2021Article
- Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.Frontiers in immunology · 2021Article
- Advances in Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles.Frontiers in bioengineering and biotechnology · 2021Review
- Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System.International journal of nanomedicine · 2021Review
- Dark-Side of Exosomes.Advances in experimental medicine and biology · 2021Article
- Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools.Diagnostics (Basel, Switzerland) · 2020Review
- [Research Progress on Exosome in Malignant Tumors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy.International journal of molecular sciences · 2020Review
- Review
- RETRACTED: miR-135b Delivered by Gastric Tumor Exosomes Inhibits FOXO1 Expression in Endothelial Cells and Promotes AngiogenesisMolecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Review
- Therapy resistance mediated by exosomes.Molecular cancer · 2019Review
- The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications.Journal of experimental & clinical cancer research : CR · 2018Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in cancer therapy have been substantial in terms of molecular understanding of disease mechanisms, however these advances have not translated into increased survival in the majority of cancer types. One unsolved problem in current cancer therapeutics is the substantial immune suppression seen in patients. Conventionally, investigations in this area have focused on antigen-nonspecific immune suppressive molecules such as cytokines and T cell apoptosis inducing molecules such as Fas ligand. More recently, studies have demonstrated nanovesicle particles termed exosomes are involved not only in stimulation but also inhibition of immunity in physiological conditions. Interestingly, exosomes secreted by cancer cells have been demonstrated to express tumor antigens, as well as immune suppressive molecules such as PD-1L and FasL. Concentrations of exosomes from plasma of cancer patients have been associated with spontaneous T cell apoptosis, which is associated in some situations with shortened survival. In this paper we place the "exosome-immune suppression" concept in perspective of other tumor immune evasion mechanisms. We conclude by discussing a novel therapeutic approach to cancer immune suppression by extracorporeal removal of exosomes using hollow fiber filtration technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.